Vermillion: Losses Doubled In 2014

AUSTIN, Texas, March 25, 2015 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, reported on its results for the fourth quarter ended and full year ended December 31, 2014.

"We are very pleased to have completed our new commercial agreement with Quest Diagnostics as well as increase the market in which we offer ASPiRA Labs' OVA1 testing service," stated Valerie Palmieri, President and CEO of Vermillion, Inc.

Help employers find you! Check out all the jobs and post your resume.

Back to news